Hongyan Liu
5PUBLICATIONS
20CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Dec 12, 2025
Efficacy, Mechanisms, and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients: A Randomized, Double-Blind, Placebo-Controlled Trial.Vikas S Sridhar, Luxcia Kugathasan, Yuliya Lytvyn
|Dec 05, 2025
Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.Vikas S Sridhar, Luxcia Kugathasan, Yuliya Lytvyn
|May 28, 2022
SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.Hongyan Liu, Vikas S Sridhar, Bruce A Perkins
|Jul 12, 2021
Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes.Hongyan Liu, Vikas S Sridhar, Daniel Montemayor
|Jan 13, 2021
Changes in Cardiovascular Biomarkers Associated With the Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Ertugliflozin in Patients With Chronic Kidney Disease and Type 2 Diabetes.Patrick R Lawler, Hongyan Liu, Claudia Frankfurter
Pageof 1
Frequent Collaborators
4 joint publications
David Z I Cherney
3 joint publications
Leif Erik Lovblom
2 joint publications
Dylan Burger
2 joint publications
Luxcia Kugathasan
2 joint publications
Yuliya Lytvyn
2 joint publications
Massimo Nardone
2 joint publications
Bruce A Perkins
2 joint publications
Hiddo J L Heerspink
2 joint publications
Jasper Stevens
2 joint publications
Daan J Touw
